fda compounding semaglutide enforcement october 2025 altRx GLP-1 Review 2026: Updated for the Latest FDA Compounded Semaglutide Action - Pricing, Refund Policy, and What's Changing

September 15, 2025: Telehealth company must stop implying its compounded GLP-1 is FDA-approved, warns FDA – Partnership for Safe Medicines

26.27

★★★★☆4.8 (126)

The FDA has removed semaglutide injection products (GLP-1) from the shortage list, ending the temporary rule that allowed pharmacies to compound these medications, often used for weight loss. Compounded drugs are custom-made

25.91

★★★★★4.9 (98)

Best Semaglutide Options for 2026: New Oral Wegovy Pill Approved by FDA as Patients Compare Injectable and Compounded Access Pathways

28.97

★★★★★5.0 (157)

The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide

26.08

★★★★★4.7 (84)

Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP-1 compounding while @martymakary is photographed holding bootleg #

20.84

★★★★★4.9 (203)

Compound versions of GLP-1 drugs for weight loss halted by FDA

23.42

★★★★★5.0 (176)

FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified

29.92

★★★★★4.8 (132)